Epalrestat, an Aldose Reductase Inhibitor, Restores Erectile Function in Streptozocin-induced Diabetic Rats

International Journal of Impotence Research
Bai-Bing YangY Dai

Abstract

Epalrestat, an aldose reductase inhibitor (ARI), was adopted to improve the function of peripheral nerves in diabetic patients. The aim of this study was to investigate whether epalrestat could restore the erectile function of diabetic erectile dysfunction using a rat model. From June 2016, 24 rats were given streptozocin (STZ) to induce the diabetic rat model, and epalrestat was administered to ten diabetic erectile dysfunction (DED) rats. Intracavernous pressure (ICP) and mean systemic arterial pressure (MAP), levels of aldose reductase (AR), nerve growth factor (NGF), neuronal nitric oxide synthase (nNOS), α-smooth muscle antigen (α-SMA), and von Willebrand factor (vWF) in the corpus cavernosum were analyzed. We discovered that epalrestat acted on cavernous tissue and partly restored erectile function. NGF and nNOS levels in the corpora were increased after treatment with epalrestat. We also found that the content of α-SMA-positive smooth muscle cells and vWF-positive endothelial cells in the corpora cavernosum were declined. Accordingly, epalrestat might improve erectile function by increasing the upregulation of NGF and nNOS to restore the function of the dorsal nerve of the penis.

References

Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·H VlassaraR Bucala
Oct 1, 1990·The Journal of Diabetic Complications·A J Green, J B Jaspan
Nov 1, 1995·Developmental Dynamics : an Official Publication of the American Association of Anatomists·K M McHugh
Aug 25, 2001·Annual Review of Neuroscience·E J Huang, L F Reichardt
Mar 20, 2003·Current Diabetes Reports·Donald Richardson, Aaron Vinik
Oct 29, 2003·Journal of Andrology·Trinity J BivalacquaWayne J G Hellstrom
Nov 9, 2004·The Journal of Clinical Endocrinology and Metabolism·Hoong Sern LimAndrew D Blann
Jul 20, 2005·Treatments in Endocrinology·Yoji Hamada, Jiro Nakamura
Jan 21, 2006·The Journal of Sexual Medicine·Tom F LueGorm Wagner
Mar 2, 2006·European Journal of Pharmacology·Nigel A CalcuttAndrew P Mizisin
Jun 22, 2006·Journal of the Peripheral Nervous System : JPNS·Masayuki BabaUNKNOWN Aomori Diabetic Study (ADNS) Group
Aug 8, 2006·The Journal of Urology·Arthur L Burnett, Tom F Lue
Aug 8, 2006·Asian Journal of Andrology·Charles R Moore, Run Wang
Oct 19, 2007·The Cochrane Database of Systematic Reviews·C ChalkF Moore
May 2, 2008·Pharmacotherapy·Mary Ann Ramirez, Nancy L Borja
Mar 17, 2009·The Journal of Sexual Medicine·Anthony J BellaTom F Lue
Apr 4, 2009·Journal of Andrology·Biljana MusickiTrinity J Bivalacqua
Feb 22, 2013·Experimental and Clinical Endocrinology & Diabetes : Official Journal, German Society of Endocrinology [and] German Diabetes Association·O NakagakiT Atsumi

❮ Previous
Next ❯

Citations

May 21, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Patrick Kwabena OduroQilong Wang
Sep 2, 2020·European Journal of Medicinal Chemistry·Antonios KousaxidisAthina Geronikaki
Oct 16, 2021·Annals of Neurology·Anna N LigezkaEva Morava

❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation

Software Mentioned

SPSS
Image
Pro Plus

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.